Jiangsu Wanhai Medical Instruments Co., Ltd., a leading Chinese developer of drug delivery systems, has finalized an agreement with the West Taihu Lake Science and Technology Industrial Park to build a state-of-the-art manufacturing facility. The 390-million-yuan investment will scale the company's annual production capacity to 310 million units, including reusable pen injector, disposable (pre-filled) pen injector, and auto-injector.

Since its founding in 2016, Wanhai Medical has emerged as China’s dominant provider of alternative drug delivery solutions, supporting therapies across diabetes management (insulin), GLP-1 agonists (weight loss and diabetes), biologics (monoclonal antibodies), and hormone replacement. The company holds more than 60 patents for injection mechanisms and safety innovations, supplying nearly 200 pharmaceutical firms, including Tonghua Dongbao and GeneScience Pharma, with devices approved in more than 60 global markets.

The global market for patient-friendly auto-injectors and pen systems is projected to grow at a 7.9% CAGR through 2030, fueled by rising diabetes prevalence and increasing biologics adoption. Wanhai Medical’s fully integrated manufacturing model—spanning proprietary mold design, advanced polymer processing, and automated assembly—enables 40–60% cost savings compared to Western competitors such as Novo Nordisk and Eli Lilly & Co’s device divisions.

In a strategic push into regulated markets, Wanhai Medical is pursuing FDA 510(k) clearance for its next-generation auto-injector system, followed by an EU MDR submission in 2026. These approvals would position the company as China’s first domestic contract manufacturer supplying premium drug-delivery devices to global innovator pharma companies. The new Changzhou facility will implement Industry 4.0 automation, ensuring scalability for future demand in smart connected injectors and combination products.

扫一扫在手机打开当前页